ADX-629
Systemic Immune-Mediated & Metabolic Diseases
Key Facts
About Aldeyra Therapeutics
Aldeyra Therapeutics is devoted to developing next-generation medicines for immune-mediated diseases through its innovative RASP modulator platform, which targets a family of pathogenic small molecules rather than single proteins. The company's most advanced candidate, reproxalap, has demonstrated rapid activity in multiple late-stage trials for dry eye disease, though it recently received a Complete Response Letter from the FDA. Aldeyra is also developing ADX-2191, an intraocular formulation of methotrexate with Orphan Drug Designation for rare retinal conditions, and ADX-629, an oral RASP modulator for systemic diseases, positioning it to address significant unmet needs across ophthalmology and immunology.
View full company profile